The CHinese pulmOnary Embolism Multimodality Imaging-artifiCial intelligencE Study (CHOICE) is a prospective observational multi-center study that will collect imaging text data and raw data of patients with pulmonary embolism (PE) in China. By combining artificial intelligence technology, it aims to identify imaging markers to assist in early diagnosis, differential diagnosis, risk stratification, and prognosis assessment of PE.
14 Years and older
Patients suspected of PE
Pregnant women
Refuse to follow up
Incomplete or discontinued imaging scans
Insufficient quality of image data to allow for analysis
Patients suspected of PE in China
Cohort
Prospective
Artificial Intelligence
DeviceAI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results
Diagnostic rate of PE
Comparison before and after AI technique.
APE risk stratification rates (low, intermediate low, intermediate high and high risk)
Comparison before and after AI technique.
Disease severity of chronic thromboembolic pulmonary disease (CTEPD)/chronic thromboembolic pulmonary hypertension (CTEPH)
Comparison before and after AI technique. Assessment of disease severity is comprehensive, referring to the comprehensive risk assessment in pulmonary arterial hypertension (three-strata model) \[DOI: 10.1183/13993003.00879-2022\], including clinical observations and modifiable variables. The higher the score, the more severe the condition.
30 day mortality
Patient mortality (death) at 30-days post-PE diagnosis. Comparison before and after AI technique.
Rate of discordant PE cases
False positive and false negative rate
AI failure rate for PE detection
Proportion of scans unable to be interpreted by AI despite suitable CTPA acquisition
12 month mortality
Patient mortality (death) at 12-months post-PE diagnosis. Comparison before and after AI technique.
Length of hospital stay for PE
Comparison before and after AI technique. Measured as number of days from admission to time of discharge from hospital.
Click on the lead sponsor to view all of their trials.
